Free Trial
NASDAQ:PMN

ProMIS Neurosciences Q3 2023 Earnings Report

ProMIS Neurosciences logo
$0.50 +0.02 (+5.13%)
Closing price 05/29/2025 03:47 PM Eastern
Extended Trading
$0.50 +0.00 (+0.08%)
As of 05/29/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProMIS Neurosciences EPS Results

Actual EPS
-$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ProMIS Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ProMIS Neurosciences Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, November 13, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

ProMIS Neurosciences' Q2 2025 earnings is scheduled for Thursday, August 14, 2025

Earnings Documents

ProMIS Neurosciences Earnings Headlines

Elon Musk’s Frightening Warning Forces Trump’s Hand
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.
ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
See More ProMIS Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProMIS Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProMIS Neurosciences and other key companies, straight to your email.

About ProMIS Neurosciences

ProMIS Neurosciences (NASDAQ:PMN) discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

View ProMIS Neurosciences Profile

More Earnings Resources from MarketBeat